Spero Therapeutics (SPRO) Current Deferred Revenue (2016 - 2025)

Spero Therapeutics (SPRO) has 8 years of Current Deferred Revenue data on file, last reported at $258000.0 in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue fell 29.89% year-over-year to $258000.0; the trailing twelve-month figure through Dec 2025 stood at $258000.0 (down 29.89% YoY), and the FY2025 full-year result was $258000.0, down 29.89% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $258000.0, down from $368000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $28.4 million in Q1 2024 and bottomed at $258000.0 in Q4 2025.
• The 5-year median for Current Deferred Revenue is $6.4 million (2022), against an average of $10.3 million.
• The widest annual swing landed in 2022, when Current Deferred Revenue jumped 514.6%; it then tumbled 98.53% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $1.9 million in 2021, then soared by 123.42% to $4.1 million in 2022, then jumped by 502.1% to $25.0 million in 2023, then sank by 98.53% to $368000.0 in 2024, then slipped by 29.89% to $258000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $258000.0 (Q4 2025), $368000.0 (Q4 2024), and $25.1 million (Q3 2024), per Business Quant data.

Peer Comparison